Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
2003 StandoutScience
Shortwave infrared fluorescence imaging with the clinically approved near-infrared dye indocyanine green
2018 StandoutNobel
Tumor imaging by means of proteolytic activation of cell-penetrating peptides
2004 StandoutNobel
Breast Cancer Metastasis to the Central Nervous System
2005
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Prognosis of Women With Metastatic Breast Cancer by HER2 Status and Trastuzumab Treatment: An Institutional-Based Review
2009
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy
2005
Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer.
2003
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
2015
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
2007
Phase II Study of Celecoxib and Trastuzumab in Metastatic Breast Cancer Patients Who Have Progressed after Prior Trastuzumab-Based Treatments
2004
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy With Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of a Randomized Trial in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer
2005
Herceptin: mechanisms of action and resistance
2005
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
2004
Phase II Study of Weekly Docetaxel and Trastuzumab for Patients With HER-2–Overexpressing Metastatic Breast Cancer
2002
Trastuzumab and cardiac dysfunction: update on preclinical studies
2003
Biologic and therapeutic role of HER2 in cancer
2003
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
2008 StandoutNature
Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer
2004
Defining prognosis for women with breast cancer and CNS metastases by HER2 status
2008
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Chemotherapy and Herceptin for HER-2+ Metastatic Breast Cancer: The Best Drug?
2001
Prognostic Significance of Human Epidermal Growth Factor Receptor Positivity for the Development of Brain Metastasis After Newly Diagnosed Breast Cancer
2006
Primary breast cancer phenotypes associated with propensity for central nervous system metastases
2006
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2019
2019 Standout
Cancer statistics, 2018
2018 Standout
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
2009 Standout
Homozygous Inactivation of theNF1Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders
1997
EGFR Antagonists in Cancer Treatment
2008 Standout
The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial
1992
Detection of heterozygous mutations in BRCA1 using high density oligonucleotide arrays and two–colour fluorescence analysis
1996
A view on drug resistance in cancer
2019 StandoutNature
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Racial Disparities in Cancer Survival Among Randomized Clinical Trials Patients of the Southwest Oncology Group
2009
Breast Cancers With Brain Metastases are More Likely to be Estrogen Receptor Negative, Express the Basal Cytokeratin CK5/6, and Overexpress HER2 or EGFR
2006
Metronomic therapy for breast cancer
2004
Contribution ofBRCA1Mutations to Ovarian Cancer
1997
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
1994
Trastuzumab: triumphs and tribulations
2007
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2
1996
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tumor Metastasis: Molecular Insights and Evolving Paradigms
2011 Standout
Isolation of rare circulating tumour cells in cancer patients by microchip technology
2007 StandoutNature
Survival of Blacks and Whites After a Cancer Diagnosis
2002
The Evolving Landscape of Brain Metastasis
2018
Trastuzumab‐associated cardiotoxicity
2002
Systematic review of bisphosphonates for hypercalcaemia of malignancy
2004
Risk factors for brain relapse in patients with metastatic breast cancer
2004
Hypercalcemia Associated with Cancer
2005
Nuclear factor-κB in cancer development and progression
2006 StandoutNature
Mutations and Polymorphisms in the familial early-onset breast cancer (BRCA1) gene
1996
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%
1996
Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer
1996
Predominance of the basal type and HER-2/neu type in brain metastasis from breast cancer
2007
Angiogenesis in life, disease and medicine
2005 StandoutNature
Anticancer drugs and cardiotoxicity: Insights and perspectives in the era of targeted therapy
2009
Malignant Gliomas in Adults
2008 Standout
Monoclonal antibodies as therapeutic agents for cancer
2004
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
2007 Standout
The descriptive epidemiology of female breast cancer: An international comparison of screening, incidence, survival and mortality
2012
The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi Jews
1997 Standout
Phase II study of weekly docetaxel in patients with metastatic breast cancer
2002
Cancer immunotherapy comes of age
2011 StandoutNature
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
1997 Standout
The 17q12-q21 amplicon: Her2 and topoisomerase-IIα and their importance to the biology of solid tumours
2006
Biomarkers of response and resistance to antiangiogenic therapy
2009
Jewish religion and risk of breast cancer
1996
Frequency and Carrier Risk Associated with Common BRCA1 and BRCA2 Mutations in Ashkenazi Jewish Breast Cancer Patients
1998
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Tumor metastasis: mechanistic insights and clinical challenges
2006 Standout
BRCA1Mutations in a Population-Based Sample of Young Women with Breast Cancer
1996
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Factors affecting the prognosis of breast cancer patients with brain metastases
2008
The anti-angiogenic basis of metronomic chemotherapy
2004 Standout
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Molecular mechanisms and clinical applications of angiogenesis
2011 StandoutNature
The HER2 Extracellular Domain as a Prognostic and Predictive Factor in Breast Cancer
2002
Angiogenesis as a therapeutic target
2005 StandoutNature
Tumor Angiogenesis
2008 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration
2009 Standout
Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer
1999
Cancer of the Ovary
2004 Standout
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
2005
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Selective Colorimetric Detection of Polynucleotides Based on the Distance-Dependent Optical Properties of Gold Nanoparticles
1997 StandoutScience
The gastric marginal zone B-cell lymphoma of MALT type
2000
Normalization of the Vasculature for Treatment of Cancer and Other Diseases
2011
Trastuzumab in the management of early and advanced stage breast cancer.
2007
Prospective, Randomized Comparison of High-Dose Chemotherapy With Stem-Cell Support Versus Intermediate-Dose Chemotherapy After Surgery and Adjuvant Chemotherapy in Women With High-Risk Primary Breast Cancer: A Report of CALGB 9082, SWOG 9114, and NCIC MA-13
2005
A Perspective on Cancer Cell Metastasis
2011 StandoutScience
Clinical Cardiac Tolerability of Trastuzumab
2004
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
Trastuzumab and Vinorelbine as First-Line Therapy for HER2-Overexpressing Metastatic Breast Cancer: Multicenter Phase II Trial With Clinical Outcomes, Analysis of Serum Tumor Markers as Predictive Factors, and Cardiac Surveillance Algorithm
2003
Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2
2004
A Pictet-Spengler ligation for protein chemical modification
2012 StandoutNobel
Cancer statistics, 2016
2016 Standout
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Pharmacokinetics, Safety, and Efficacy of Trastuzumab Administered Every Three Weeks in Combination With Paclitaxel
2003
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
2005 StandoutScience
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
The gastric marginal zone B-cell lymphoma of MALT type
2000
Global cancer statistics, 2012
2015 Standout
Multiple Myeloma
2011 Standout
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
Metastatic Behavior of Breast Cancer Subtypes
2010 Standout
Phase II Study of Efficacy, Safety, and Pharmacokinetics of Trastuzumab Monotherapy Administered on a 3-Weekly Schedule
2005
CNS Metastases in Breast Cancer
2004
Works of Jerry Younger being referenced
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
2001
Preoperative Therapy With Trastuzumab and Paclitaxel Followed by Sequential Adjuvant Doxorubicin/Cyclophosphamide for HER2 Overexpressing Stage II or III Breast Cancer: A Pilot Study
2002
Central nervous system metastases in women who receive trastuzumab‐based therapy for metastatic breast carcinoma
2003
Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
2008
Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer
2001
A Feasibility Study of Intensive CAF as Outpatient Adjuvant Therapy for Stage II Breast Cancer in a Cooperative Group: CALGB 8443
1990
Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages
1993
Predictors of skeletal complications in patients with metastatic breast carcinoma
2000
The non-breast-cancer death rate among breast cancer patients
2010
Mucosa-associated lymphoid tissue lymphoma of the stomach
1999
Germ-LineBRCA1Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer
1996
Race and survival from breast cancer: based on Cancer and Leukemia Group B trial 8541.
1997
Phase II trial of lapatinib for brain metastases in patients with HER2+ breast cancer
2006
Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer
2000
VEGF as a Marker for Outcome Among Advanced Breast Cancer Patients Receiving anti-VEGF Therapy with Bevacizumab and Vinorelbine Chemotherapy
2008